<DOC>
	<DOCNO>NCT02302547</DOCNO>
	<brief_summary>In early 2000s , `` TRILEGE© '' study realize determine reductive anti retroviral strategy initial triple therapy ( base protease inhibitor third agent ) towards dual therapy nucleoside analog ( particular association `` zidovudine +lamivudine '' ) patient infect HIV stabilize least 3 month threshold value 400 copies/ml , would allow obtain well-controlled plasmatic viral load , aim reduce long-term side effect treatment . The afore mention study show reductive anti retroviral strategy failure . No study yet revaluate strategy , particular current context antiretroviral treatment . Indeed , modern nucleoside inhibitor ( Kivexa® , Truvada® ) extend half-lives well superior intrinsic power compare treatment propose initial `` TRILEGE© '' study . Furthermore , good quality current triple therapy ( compare use 10 year ago ) lead substantial viral reservoir reduction . Currently , small number patient successfully treat long-term ( viral load &lt; 20 copies/ml ) use nucleoside analog dual therapy . The particular characteristic patient yet thoroughly investigate . The patient concern treat prematurely ever pass 200 lymphocyte T CD4/mm3 . It occur patient present low viral reservoir measure HIV DNA quantification ( &lt; 2,7 log copies/106 PBMC ) . Therefore , target patient ( 1 ) strong immune restoration , ( 2 ) low HIV DNA value ( 3 ) good observance , investigator emit hypothesis , reductive anti retroviral strategy would consist change conventional triple therapy towards Nucleoside reverse-transcriptase inhibitor dual therapy , could allow durable control viral replication concomitant benefice reduce antiretroviral side effect cost .</brief_summary>
	<brief_title>Trial Evaluate Interest Reductive Anti Retroviral Strategy Using Dual Therapy Inspite Triple Therapy</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV1 infect patient Initial TT ARV start ( equal ) 150 / mm3 LT CD4 , 18 month prior inclusion study Ongoing antiretroviral therapy combine tenofovir + emtricitabine + 3rd agent ( IP / r , IP , NNRTI , II , Inhibitors ) least one undetectable viral load ( CV &lt; 50 copy / mL ) introduction latter treatment . Patient virological success : CV &lt; 50 copy / mL least 12 month , include visit selection . Absence previous therapeutic failure : viral load ≥ 200 copy / mL ( 6 month treatment ) ( Except case justify therapeutic interruption : travel , stockout ... ) obtain success Virologic introduction treatment , without concept genotypic resistance know ARVs use . Cellular DNAHIV &lt; 2.7 log copy / 106 PBMC Zenith RNAHIV &lt; 150,000 copy / ml ( exclude viral load value primary infection document ) No genotypic resistance currently use know ARVs Patient give write informed consent Affiliate beneficiary social security scheme Patient follow outpatient basis , age ≥ 18 year . Noncompliant patient Subject pregnant , lactating , childbearing potential without contraception Active opportunistic infection Major overweight ( BMI ≥ 40 ) Severe renal pathology ( creatinine clearance &lt; 30ml/min ) Cirrhosis severe liver failure ( factor V &lt; 50 % ) Prognosis threaten within 6 month Circumstances may impair judgment understand information give patient Malabsorption syndromes The following laboratory criterion : Serum ASAT , ALAT &gt; 5 x upper limit normal ( ULN ) Thrombocytopenia platelet count &lt; 50.000/ml Anemia hemoglobin &lt; 8g/dl Polynuclear neutrophil count &lt; 500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV-DNA</keyword>
	<keyword>dual therapy</keyword>
	<keyword>NRTI</keyword>
	<keyword>virological control</keyword>
	<keyword>truvada®</keyword>
</DOC>